Insider trade

Officer sold ~$2.01M of EW shares in the open market

Traded Feb 25, 2026 · Filed Feb 27, 2026

~$2.01M
Reported value · 24K sh @ $83.8365: 21K
Holds after · shares reported: +2.1%
stock since the trade · S&P 500 +10.2%, $83.40 → $85.19 on Oct 1

Why it stands out

Edwards Lifesciences's CVP,Strategy/Corp Development sold $2.01M of Edwards Lifesciences shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 25, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 27, 2026

Officer$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,012,076

Shares × reported transaction price

Timing vs results

15 days after results of Feb 10, 2026, 57 days before results of Apr 23, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $83.40 on Feb 25, 2026, within 5% of its 52-week high, little changed over the previous 30 trading days

52-week range $67.07 (Apr 8, 2025) to $86.94 (Dec 29, 2025), 82% of the way up, from 251 adjusted closes. 30 trading days earlier: $83.01 on Jan 12, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.

Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	-5.6%	-2.0%	-3.6%
30 days	-8.1%	-7.9%	-0.2%
90 days	-0.6%	+10.0%	-10.6%
180 days	+5.0%	+11.7%	-6.7%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-26-002711
Filed / recorded: Feb 27, 2026, 12:33 AM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Edwards Lifesciences Corp
Issuer CIK: 1099800
Ticker: EW
Reporting person: Donald E Jr Bobo
Relationship: Officer
Officer title: CVP,Strategy/Corp Development
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Feb 25, 2026
Transaction code: S
Shares / units: 24,000
Price per share: $83.8365
Acquired / disposed: Disposed (D)
Shares owned after: 21,266.2532
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was executed in multiple trades at prices ranging from $83.66 to $83.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Total reflects the correction of 13,396 shares held indirectly by the Reporting Person's trust, which were previously reported as directly held.